Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR1 over exp |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR1 Inhibitor GSK3052230 |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR1 over exp | uterus leiomyosarcoma | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) inhibited survival of FGFR1-overexpressing uterus leiomyosarcoma cells in culture (PMID: 27535980). | 27535980 |
FGFR1 over exp | stomach cancer | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment inhibited growth of FGFR1-overexpressing gastric cancer cells in culture (PMID: 33563752). | 33563752 |
FGFR1 over exp | renal cell carcinoma | not applicable | Sorafenib | Phase II | Emerging | In a clinical analysis of a Phase II trial, high Fgfr1 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027). | 25900027 | |
FGFR1 over exp | lung cancer | predicted - sensitive | FGFR Inhibitor (Pan) | Docetaxel + Rogaratinib | Preclinical - Pdx | Actionable | In a preclinical study, the combination of Rogaratinib (BAY 1163877) and Taxotere (docetaxel) resulted in improved inhibition of tumor growth and duration of response, leading to three complete responses and seven partial responses compared to Taxotere (docetaxel) alone, resulting in only six partial responses, in lung cancer patient-derived xenograft models with FGFR1 overexpression (n=10) (PMID: 30807645). | 30807645 |
FGFR1 over exp | stomach cancer | sensitive | Regorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Stivarga (regorafenib) in an FGFR1-overexpressing gastric cancer cell line resulted in decreased phosphorylation of Fgfr2 and Erk, and inhibition of cell growth in culture (PMID: 33563752). | 33563752 | |
FGFR1 over exp | head and neck squamous cell carcinoma | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical | Actionable | In a preclinical study, Truseltiq (infigratinib) inhibited cell growth and induced apoptosis in HNSCC cells over expressing Fgfr1 in culture and in xenograft models (PMID: 26015511). | 26015511 |
FGFR1 over exp | lung cancer | predicted - sensitive | FGFR Inhibitor (Pan) | Rogaratinib | Preclinical - Pdx | Actionable | In a preclinical study, a lung cancer patient-derived xenograft (PDX) model with FGFR1 overexpression demonstrated decreased tumor volume when treated with Rogaratinib (BAY 1163877) (PMID: 30807645). | 30807645 |
FGFR1 over exp | stomach cancer | sensitive | Regorafenib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Mekinist (trametinib) restored sensitivity of gastric cancer cells with FGFR1 overexpression to Stivarga (regorafenib) treatment, demonstrating decreased Erk phosphorylation and reduced cell proliferation in culture (PMID: 33563752). | 33563752 | |
FGFR1 over exp | lung squamous cell carcinoma | no benefit | FGFR Inhibitor (Pan) | Rogaratinib | Phase II | Actionable | In a Phase II trial, Rogaratinib (BAY 1163877) treatment did not result in improved progression-free survival (PFS) of metastatic lung squamous cell carcinoma patients with overexpression of FGFR1, FGFR2, or FGFR3, as only 10% (1/10) of patients achieved 6-month PFS, further clinical development of this agent was halted (J Clin Oncol 39, no. 15_suppl (May 20, 2021) e2119; NCT03762122). | detail... |
FGFR1 over exp | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | PRN1371 | Preclinical - Cell culture | Actionable | In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing wild-type FGFR1 in culture (PMID: 28978721). | 28978721 |
FGFR1 over exp | stomach cancer | sensitive | FGFR Inhibitor (Pan) | Infigratinib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Mekinist (trametinib) restored sensitivity of gastric cancer cells with FGFR1 overexpression to Truseltiq (infigratinib) treatment, demonstrating decreased Erk phosphorylation and reduced cell proliferation in culture (PMID: 33563752). | 33563752 |
FGFR1 over exp | stomach cancer | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) treatment inhibited growth of gastric cancer cells overexpressing FGFR1 in culture (PMID: 33563752). | 33563752 |
FGFR1 over exp | Her2-receptor negative breast cancer | predicted - sensitive | FGFR1 Inhibitor | Lucitanib | Phase II | Actionable | In a Phase II (FINESSE) trial, Lucitanib (E-3810) treatment resulted in improved objective response rate (25%, 5/20 vs 8%, 3/39) and median progression-free survival (158 vs 109 days) in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer with high Fgfr1 expression (H-score>=50) compared to those with low Fgfr1 expression (H-score<50) (PMID: 31619444; NCT02053636). | 31619444 |
FGFR1 over exp | colon cancer | sensitive | FGFR Inhibitor (Pan) | Rogaratinib | Preclinical | Actionable | In a preclinical study, syngeneic colon cancer mouse models with FGFR1 over expression demonstrated antitumor activity when treated with Rogaratinib (BAY 1163877), with a partial response observed in 22% (2/9) and stable disease in one (PMID: 30807645). | 30807645 |
FGFR1 over exp | uterus leiomyosarcoma | sensitive | FGFR1 Inhibitor | PD173074 | Preclinical - Cell culture | Actionable | In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980). | 27535980 |
FGFR1 over exp | thyroid gland cancer | sensitive | FGFR Inhibitor (Pan) | Lenvatinib | Preclinical | Actionable | In a preclinical study, Lenvima (lenvatinib) inhibited FGFR1 phosphorylation and signaling in thyroid cancer cells overexpressing FGFR1 (PMID: 25295214). | 25295214 |
FGFR1 over exp | stomach cancer | sensitive | FGFR Inhibitor (Pan) | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Futibatinib (TAS-120) treatment inhibited growth of FGFR1-overexpressing gastric cancer cells in culture (PMID: 33563752). | 33563752 |
FGFR1 over exp | uterus leiomyosarcoma | sensitive | FGFR1 Inhibitor | AZD4547 | Preclinical - Cell culture | Actionable | In a preclinical study, AZD4547 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980). | 27535980 |
FGFR1 over exp | Advanced Solid Tumor | predicted - sensitive | FGFR Inhibitor (Pan) | Rogaratinib | Phase I | Actionable | In a Phase I trial, treatment with Rogaratinib (BAY 1163877) was well-tolerated and resulted in objective response rate (ORR) of 15% (15/100) in patients with FGFR1, FGFR2, or FGFR3-overexpressing advanced solid tumors, including urothelial cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer, and led to an ORR of 67% (10/15) in patients with FGFR overexpression, but without an FGFR genetic aberration (PMID: 31405822). | 31405822 |
FGFR1 over exp | Advanced Solid Tumor | sensitive | FGFR1 Inhibitor | Derazantinib | Preclinical - Cell culture | Actionable | In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Fgfr1 in culture (PMID: 27627808). | 27627808 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03473756 | Phase Ib/II | Atezolizumab Atezolizumab + Rogaratinib | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUT | 2 |
NCT03410693 | Phase II | Docetaxel Vinflunine Paclitaxel Rogaratinib | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 21 |
NCT03517956 | Phase I | Copanlisib + Rogaratinib | Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) | Completed | USA | ESP | DEU | BEL | 2 |
NCT04040725 | Phase II | Rogaratinib | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | Withdrawn | 0 | |
NCT03088059 | Phase II | Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil | Biomarker-based Study in R/M SCCHN (UPSTREAM) | Recruiting | ITA | FRA | BEL | 1 |